Shanghai Kaibao Pharmaceutical CO.,Ltd

SZSE:300039 Stock Report

Market Cap: CN¥7.2b

Shanghai Kaibao PharmaceuticalLtd Past Earnings Performance

Past criteria checks 5/6

Shanghai Kaibao PharmaceuticalLtd has been growing earnings at an average annual rate of 16.1%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 6.6% per year. Shanghai Kaibao PharmaceuticalLtd's return on equity is 9%, and it has net margins of 22.3%.

Key information

16.1%

Earnings growth rate

16.3%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate6.6%
Return on equity9.0%
Net Margin22.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

A Piece Of The Puzzle Missing From Shanghai Kaibao Pharmaceutical CO.,Ltd's (SZSE:300039) Share Price

Jul 31
A Piece Of The Puzzle Missing From Shanghai Kaibao Pharmaceutical CO.,Ltd's (SZSE:300039) Share Price

Revenue & Expenses Breakdown

How Shanghai Kaibao PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:300039 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,561349808121
30 Jun 241,577335835112
31 Mar 241,610336850104
31 Dec 231,59432885396
30 Sep 231,47326876894
30 Jun 231,42524377287
31 Mar 231,23421368167
01 Jan 231,11919162053
30 Sep 221,10614364283
30 Jun 221,10314163880
31 Mar 221,10414166072
01 Jan 221,10114065679
30 Sep 211,05511668250
30 Jun 2197011161460
31 Mar 2195411160167
31 Dec 2090810658059
30 Sep 201,00314859358
30 Jun 201,10717566652
31 Mar 201,31223276553
31 Dec 191,41925182955
30 Sep 191,41419784852
30 Jun 191,38219782138
31 Mar 191,38019982432
31 Dec 181,50122788647
30 Sep 181,46624688165
30 Jun 181,543261884100
31 Mar 181,63328193790
31 Dec 171,57027289465
30 Sep 171,55728787732
30 Jun 171,5462869040
31 Mar 171,5242908910
31 Dec 161,4972838800
30 Sep 161,4442878400
30 Jun 161,3982848140
31 Mar 161,3682748090
31 Dec 151,3962828320
30 Sep 151,5363318990
30 Jun 151,6333579530
31 Mar 151,7003639920
31 Dec 141,6213529450
30 Sep 141,5113458800
30 Jun 141,4813378640
31 Mar 141,3713307970
31 Dec 131,3233197770

Quality Earnings: 300039 has high quality earnings.

Growing Profit Margin: 300039's current net profit margins (22.3%) are higher than last year (18.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300039's earnings have grown by 16.1% per year over the past 5 years.

Accelerating Growth: 300039's earnings growth over the past year (30%) exceeds its 5-year average (16.1% per year).

Earnings vs Industry: 300039 earnings growth over the past year (30%) exceeded the Pharmaceuticals industry -1.2%.


Return on Equity

High ROE: 300039's Return on Equity (9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies